{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:16Z","timestamp":1787008516626,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030684","name":"Maruho Co. Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co. Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The biologic therapy nemolizumab has been shown to improve the signs and symptoms of prurigo nodularis (PN) to a significantly greater extent than placebo over 16 weeks of treatment. We now report efficacy and safety data over 68 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long-term impact of nemolizumab on pruritus, disease severity, quality of life (QoL) and topical corticosteroid (TCS) usage in patients with PN in Japan, and to confirm the safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Asian patients aged \u2265 13\u2005years were randomly assigned (1 : 1 : 1) to receive nemolizumab 30\u2005mg, 60\u2005mg or placebo, with concomitant medium-potency TCS, every 4 weeks for 16 weeks. For the subsequent 52 weeks, nemolizumab treatment was continued, while placebo-treated patients were reallocated to either the 30-mg or 60-mg nemolizumab groups. Efficacy outcome measures included the Peak Pruritus Numerical Rating Scale (PP-NRS), 5-level itch scale, Investigator\u2019s Global Assessment (IGA), the number of prurigo nodules, Insomnia Severity Index, Dermatology Life Quality Index and use of TCS. Safety measures included the frequency of treatment-emergent adverse events (TEAEs). The trial was registered with the Japan Registry of Clinical Trials (jRCT2011200017).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the modified intention-to-treat population (n = 226), nemolizumab provided sustained and continuing improvements in efficacy between weeks 16 and 68. In patients who received nemolizumab 30\u2005mg, PP-NRS had decreased by 60.5% at week 16 and by 78.6% at week 68; respective decreases in the 60-mg group were 55.1% and 76.5%. Across all treatment groups, a large proportion of patients experienced improvements indicating a reduction from moderate-to-severe to mild pruritus, improvements in IGA indicating a reduction in PN severity, a decrease in the number of nodules, and rapid and durable improvements in sleep and daily life activities. Nemolizumab-treated patients were also able to reduce the daily quantity of medium-potency and higher TCS used by at least half. There was no indication of relapse in pruritus, PN severity or QoL scores following treatment cessation. Most TEAEs were mild and similar to those reported in prior studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nemolizumab elicited continuous and durable improvements across multiple measures of pruritus, PN severity and QoL over 68 weeks of treatment, with no new safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf045","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T07:15:48Z","timestamp":1739862948000},"page":"56-65","source":"Crossref","is-referenced-by-count":11,"title":["Long-term (68 weeks) administration of nemolizumab and\u00a0topical corticosteroids for prurigo nodularis in\u00a0patients aged \u2265 13\u2005years: efficacy and safety data from a phase II\/III study"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-9485","authenticated-orcid":false,"given":"Hiroo","family":"Yokozeki","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-1377","authenticated-orcid":false,"given":"Hiroyuki","family":"Murota","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8469","authenticated-orcid":false,"given":"Takayo","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Clinical Development Department, Maruho Co., Ltd , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"2025062514181675100_ljaf045-B1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2025062514181675100_ljaf045-B2","doi-asserted-by":"crossref","first-page":"638325","DOI":"10.3389\/fmed.2021.638325","article-title":"Interleukin-31 as a clinical target for pruritus treatment","volume":"8","author":"Kabashima","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025062514181675100_ljaf045-B3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10091906","article-title":"Interleukin-31 and pruritic skin","volume":"10","author":"Furue","year":"2021","journal-title":"J Clin Med"},{"key":"2025062514181675100_ljaf045-B4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025062514181675100_ljaf045-B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/exd.13236","article-title":"Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody","volume":"27","author":"Oyama","year":"2018","journal-title":"Exp Dermatol"},{"key":"2025062514181675100_ljaf045-B6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"2025062514181675100_ljaf045-B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312\u2005years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025062514181675100_ljaf045-B8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025062514181675100_ljaf045-B9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"2025062514181675100_ljaf045-B10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"key":"2025062514181675100_ljaf045-B11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"Stander","year":"2020","journal-title":"N Engl J Med"},{"key":"2025062514181675100_ljaf045-B12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025062514181675100_ljaf045-B13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: epidemiology and clinical features","volume":"83","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025062514181675100_ljaf045-B14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4103\/idoj.IDOJ_324_17","article-title":"The prevalence of psychiatric comorbidity in patients with prurigo nodularis","volume":"9","author":"Dhawan","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"2025062514181675100_ljaf045-B15","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3778","article-title":"Impact of itch on sleep disturbance in patients with prurigo nodularis","volume":"101","author":"Gwillim","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2025062514181675100_ljaf045-B16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2025062514181675100_ljaf045-B17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/1744666X.2024.2306225","article-title":"A critical evaluation of nemolizumab for prurigo nodularis","volume":"20","author":"Brooks","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"2025062514181675100_ljaf045-B18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jaci.2024.02.016","article-title":"Learning from nemolizumab: a promising therapy for prurigo nodularis","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"2025062514181675100_ljaf045-B19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomised, double-blind, placebo-controlled, phase II\/III clinical study in patients aged \u2265 13\u2005years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025062514181675100_ljaf045-B20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025062514181675100_ljaf045-B21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2336\/nishinihonhifu.73.278","article-title":"Olopatadine hydrochloride in children: evidenced efficacy and safety for atopic dermatitis \u00adtreatment in a randomized, multicentre, double-blind, parallel group comparative study","volume":"73","author":"Kawashima","year":"2011","journal-title":"Nishinihon J Dermatol"},{"key":"2025062514181675100_ljaf045-B22","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3701","article-title":"Investigator's Global Assessment of chronic prurigo: a new instrument for use in clinical trials","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2025062514181675100_ljaf045-B23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","article-title":"The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response","volume":"34","author":"Morin","year":"2011","journal-title":"Sleep"},{"key":"2025062514181675100_ljaf045-B24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"2025062514181675100_ljaf045-B25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u00a0\u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2025062514181675100_ljaf045-B26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus\u00a0topical agents in patients with atopic dermatitis (AD) and\u00a0moderate-to-severe pruritus provide improvement in pruritus\u00a0and\u00a0signs of AD for up to 68 weeks: results from two\u00a0phase\u00a0III,\u00a0long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025062514181675100_ljaf045-B27","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/1346-8138.17171","article-title":"A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody","volume":"51","author":"Masuyuki","year":"2024","journal-title":"J\u00a0Dermatol"},{"key":"2025062514181675100_ljaf045-B28","first-page":"e193","article-title":"Psoriasis-like lesions in an atopic dermatitis patient possibly associated with nemolizumab treatment","volume":"51","author":"Masuda","year":"2023","journal-title":"J Dermatol"},{"key":"2025062514181675100_ljaf045-B29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1684\/ejd.2023.4566","article-title":"Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis","volume":"33","author":"Kamada","year":"2023","journal-title":"Eur J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf045\/62495297\/ljaf045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/56\/62495297\/ljaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/1\/56\/62495297\/ljaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T14:18:26Z","timestamp":1750861106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/1\/56\/8088394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,21]]},"published-print":{"date-parts":[[2025,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf045","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,21]]}}}